Specialty Pharmacy

The study evaluated the activity and tolerability of venetoclax combined with cytarabine or cytarabine/idarubicin in pediatric patients with relapsed/refractory acute myeloid leukemia.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Valoctocogene roxaparvovec (BioMarin) met pre-specified criteria for Factor VIII activity levels treating severe hemophilia A in a phase 3 clinical trial.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

A group of health care providers, including 17 pharmacists, indicated in a recent survey that although they believe that medical marijuana likely provides benefits for patients with cancer, less than half were comfortable recommending its use.

Specialty Pharmacy Times® is on site at the American Society of Clinical Oncology Annual Meeting to provide you with coverage of the conference in real time.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Nearly half of evaluable patients with rare central nervous system tumors, neuroblastoma, or other solid tumors had responses to entrectinib.

Lowest test dose of oxaliplatin and capecitabine was comparable to the highest dose in delaying advanced gastroesophageal cancer progression and minimizing adverse effects.

Lenalidomide found to prevent the formation of blood vessels that feed tumors, yet carries significant adverse effects.

As more novel therapies emerge from the pipeline and enter the market, it is crucial for pharmacists to monitor new drug approvals that could be lifechanging for their patients.

Gilteritinib (Xospata, Astellas Pharma) is indicated for adults with relapsed/refractory acute myeloid leukemia with an FMS-like tyrosine kinase 3 mutation.

Top news of the day from across the health care landscape.

A ‘fail-first’ policy by the Centers for Medicare and Medicaid Services could be a nightmare for patients with cancer, according to the Community Oncology Alliance.

The importance of improving the specialty pharmacy experience for patients newly diagnosed with a life-changing disease.

Many patients with pancreatic cancer do not receive cancer-directed treatment that may extend survival.

Top news of the day from across the health care landscape.

Officials with the FDA today approved lenalidomide (Revlimid, Celgene) in combination with a rituximab product (R2) for the treatment of adult patients with previously-treated follicular lymphoma or marginal zone lymphoma.

The new indication makes cariprazine the first and only dopamine and serotonin partial agonist to treat the full spectrum of bipolar I symptoms in manic, mixed, and depressive episodes.

Genomic data may improve the selection of more precise models for metastatic breast cancer research.

Top news of the day from across the health care landscape.

Matthew Malachowski, PharmD, BCPS, supervisor of specialty pharmacy services at UAB Health System, provides insight into some of the challenges associated with establishing or expanding specialty pharmacy services and how to overcome them.

National Cancer Institute-Children’s Oncology Group Pediatric Molecular Analysis for Therapy Choice is the first nationwide precision oncology trail for patients with cancers that have not responded to standard treatments.

Officials with the FDA approved ruxolitinib (Jakafi, Incyte), the first treatment for patients 12 years and older with steroid-refractory acute graft-versus-host disease.

The drug, onasemnogene abeparvovec-xioi (Zolgensma, AveXis), is an adeno-associated virus vector-based gene therapy that targets the cause of SMA, a leading genetic cause of infant mortality.

Top news of the week from Specialty Pharmacy Times.

Researchers seek to investigate how to broaden the potential of cediranib with and olaparib to treat multiple cancer types.

Top news of the day from across the health care landscape.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.